Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

The Lancet Respiratory Medicine

Volumn 7, Issue 11, 2019, Pages 951-963

  Davey, Richard T ^a,o   Fernández Cruz, Eduardo ^b,o   Markowitz, Norman ^c,o   Pett, Sarah ^d,o   Babiker, Abdel G ^d,o   Wentworth, Deborah ^e,o   Khurana, Surender ^f,o   Engen, Nicole ^e,o   Gordin, Fred ^g,o   Jain, Mamta K ^h,o   Kan, Virginia ^g,o   Polizzotto, Mark N ^i,o   Riska, Paul ^j,o   Ruxrungtham, Kiat ^k,l,o   Temesgen, Zelalem ^m,o   Lundgren, Jens ^n,o   Beigel, John H ^a,o   Lane, H Clifford ^a,o   Neaton, James D ^e,o   Butts, Jessica ^o   Denning, Eileen ^o   DuChene, Alain ^o   Krum, Eric ^o   Harrison, Merrie ^o   Meger, Sue ^o   Peterson, Ross ^o   Quan, Kien ^o   Shaughnessy, Megan ^o   Thompson, Greg ^o   Vock, David ^o   Metcalf, Julia ^o   Dewar, Robin ^o   Rehman, Tauseef ^o   Natarajan, Ven ^o   McConnell, Rose ^o   Flowers, Emily ^o   Smith, Kenny ^o   Hoover, Marie ^o   Coyle, Elizabeth M ^o   Munroe, David ^o   Aagaard, Bitten ^o   Pearson, Mary ^o   Cursley, Adam ^o   Webb, Helen ^o   Hudson, Fleur ^o   Russell, Charlotte ^o   Sy, Aminata ^o   Purvis, Cara ^o   Jackson, Brooke ^o   Collaco Moraes, Yolanda ^o   Carey, Dianne ^o   Robson, Rosemary ^o   Sánchez, Adriana ^o   Finley, Elizabeth ^o   Conwell, Donna ^o   Losso, Marcelo H ^o   Gambardella, Luciana ^o   Abela, Cecilia ^o   Lopez, Paco ^o   Alonso, Helena ^o   Touloumi, Giota ^o   Gioukari, Vicky ^o   Anagnostou, Olga ^o   Avihingsanon, Anchalee ^o   Pussadee, Kanitta ^o   Ubolyam, Sasiwimol ^o   Omotosho, Bola ^o   Solórzano, Clemencia ^o   Petersen, Tianna ^o   Vysyaraju, Kranthi ^o   Rizza, Stacey A ^o   Whitaker, Jennifer A ^o   Nahra, Raquel ^o   Baxter, John ^o   Coburn, Patricia ^o   Gardner, Edward M ^o   Scott, James A ^o   Faber, Leslie ^o   Pastor, Erica ^o   Makohon, Linda ^o   MacArthur, Rodger A ^o   Hillman, L Monique ^o   Farrough, Marti J ^o   Polenakovik, Hari M ^o   Clark, Linda A ^o   Colon, Roberto J ^o   Kunisaki, Ken M ^o   DeConcini, Miranda ^o   Johnson, Susan A ^o   Wolfe, Cameron R ^o   Mkumba, Laura ^o   Carbonneau, June Y ^o   Morris, Alison ^o   Fitzpatrick, Meghan E ^o   Kessinger, Cathy J ^o   Salata, Robert A ^o   Arters, Karen A ^o   Tasi, Catherine M ^o   Panos, Ralph J ^o   Lach, Laura A ^o   Glesby, Marshall J ^o   Ham, Kirsis A ^o   Hughes, Valery G ^o   Schooley, Robert T ^o   Crouch, Daniel ^o   Muttera, Leticia ^o   Novak, Richard M ^o   Bleasdale, Susan C ^o   Zuckerman, Ariel E ^o   Manosuthi, Weerawat ^o   Thaonyen, Supeda ^o   Chiewcharn, Thaniya ^o   Suwanpimolkul, Gompol ^o   Gatechumpol, Sivaporn ^o   Bunpasang, Sirikunya ^o   Angus, Brian J ^o   Anderson, Monique ^o   Morgan, Marcus ^o   Minton, Jane ^o   Gkamaletsou, Maria N ^o   Hambleton, Joe ^o   Price, David A ^o   Llewelyn, Martin J ^o   Sweetman, Jonathan ^o   Carbone, Javier ^o   Arribas, Jose R ^o   Montejano, Rocio ^o   Lobo Beristain, Jose L ^o   Martinez, Iñaki Z ^o   Barberan, Jose ^o   Hernandez, Paola ^o   Dwyer, Dominic E ^o   Kok, Jen ^o   Borges, Alvaro ^o   Brandt, Christian T ^o   Knudsen, Lene S ^o   Sypsas, Nikolaos ^o   Constantinou, Costas ^o   Markogiannakis, Antonios ^o   Zakynthinos, Spyros ^o   Katsaounou, Paraskevi ^o   Kalomenidis, Ioannis ^o   Mykietiuk, Analia ^o   Alzogaray, Maria F ^o   Obed, Mora ^o   Macias, Laura M ^o   Ebensrtejin, Juan ^o   Burgoa, Patricia ^o   Nannini, Esteban ^o   Lahitte, Matias ^o   Perez Patrigeon, Santiago ^o   Martínez Orozco, José Arturo ^o   Ramírez Hinojosa, Juan Pablo ^o   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HENRY FORD HOSPITAL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MINNESOTA   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j MONTEFIORE MEDICAL CENTER   (United States)

^k CHULALONGKORN UNIVERSITY   (Thailand)

^l THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^m MAYO CLINIC   (United States)

ⁿ Rigshospitalet   (Denmark)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO; ANTIVIRUS AGENT; OSELTAMIVIR;

ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH HAZARD; HEMAGGLUTINATION INHIBITION; HOSPITAL DISCHARGE; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL EARLY WARNING SCORE; PHARMACIST; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; CLINICAL TRIAL; COMBINATION DRUG THERAPY; HOSPITALIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS; INFLUENZAVIRUS B; MULTICENTER STUDY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INFLUENZAVIRUS B; MALE; MIDDLE AGED; OSELTAMIVIR; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 85073543690     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(19)30253-X     Document Type: Article

References (30)

1. Iuliano AD, Roguski K, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018; 391: 1285–300.
2. Cilek L, Chowell G, Farinas R. Age-specific excess mortality patterns during the 1918–1920 influenza pandemic in Madrid, Spain. Am J Epidemiol 2018; 187: 2511–23.
3. Paules C, Subbarao K. Influenza. Lancet 2017; 390: 697–708.
4. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomized controlled trials. Lancet 2015; 385: 1729–37.
5. Ramirez J, Peyrani P, Wiemken T, et al. A randomized study evaluating the effectiveness of oseltamivir initiated at the time of hospital admission in adults hospitalized with influenza-associated lower respiratory tract infections. Clin Infect Dis 2018; 67: 736–42.
6. Johnson NPAS, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med 2002; 76: 105–15.
7. Luke TR, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: future H5N1 treatment? Ann Intern Med 2006; 145: 599–609.
8. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory analysis. J Infect Dis 2015; 211: 80–90.
9. Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med 2017; 5: 500–11.
10. Beigel JH, Aga E, Elie-Turenne M-C, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med 2019; published online Sept 30. https://doi.org/10.1016/S2213-2600(19)30199-7.
11. Hung Ivan FN, To Kelvin KW, Lee Cheuk-Kwong, et al. Hyperimmune IV immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 2013; 144: 464–73.
12. Royal College of Physicians of London. National early warning score (NEWS): standardising the assessment of acute-illness severity in the NHS. 2012. www.rcplondon.ac.uk/resources/national-early-warning-score-news (accessed Feb 27, 2019).
13. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3: 85ra48.
14. INSIGHT FLU005 IVIG Pilot Study Group. INSIGHT FLU005: an anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. J Infect Dis 2016; 213: 574–78.
15. Ohmit SE, Petrie JG, Cross RT, et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204: 1879–85.
16. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767–77.
17. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza viruses. 2007. https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Guidance-for-Industry–Clinical-Data-Needed-to-Support-the-Licensure-of-Pandemic-Influenza-Vaccines.pdf (accessed Aug 12, 2019).
18. Peterson RL, Vock DM, Powers JM, et al. Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin Trials 2017; 14: 264–76.
19. National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0, December 2004, clarification August 2009. 2004. https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf (accessed Aug 12, 2019).
20. Whitehead J. Sample size calculations for ordered categorical data. Stat Med 1993; 12: 2257–71.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–56.
22. Lan KG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659–63.
23. Agresti A, Kateri M. Categorical data analysis. In: Lovric M, ed. International encyclopedia of statistical science. Berlin, Heidelberg: Springer, 2011.
24. Murray GD, Barer D, Choi S, et al. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma 2005; 22: 511–17.
25. Rockman S, Lowther S, Camuglia S, et al. Intravenous immunoglobulin protects against severe pandemic influenza infection. EBioMedicine 2017; 19: 119–27.
26. Cowling BJ, Lim WW, Perera RAPM, et al. Influenza hemagluttination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B. Clin Infect Dis 2018; published online Sept 8. DOI:10.1093/cid/ciy759.
27. Gao R, Bhatnagar J, Blau DM, et al. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1): role of the host immune response in pathogenesis. Am J Pathol 2013; 183: 1258–68.
28. Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate of (cross-) protective immunity against influenza. Vaccine 2015; 33: 500–06.
29. Sicca F, Neppelenbroek S, Huckriede A. Effector mechanisms of influenza-specific antibodies: neutralization and beyond. Expert Rev Vaccines 2018; 17: 785–95.
30. Khurana S, Coyle EM, Verma S, et al. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine. Vaccine 2014; 32: 6421–32.